Fatty liver disease affects millions worldwide, yet current treatment options remain frustratingly limited. This therapeutic gap may soon narrow thanks to the discovery of a previously unknown molecular pathway that appears central to disease progression.
Researchers have identified a critical ligand-receptor interaction involving glycoprotein GPNMB and its newly discovered receptor RYK that drives metabolic-dysfunction-associated steatohepatitis (MASH). The study found that eliminating GPNMB—among the most upregulated genes in MASH—protected mice from diet-induced liver damage. Crucially, only the secreted fragment of GPNMB, not the full protein, promotes disease progression. In human patients, blood levels of this secreted fragment correlated strongly with MASH severity, suggesting diagnostic potential.
The mechanism involves GPNMB binding to RYK receptors on liver cells, triggering ERK1/2 signaling that activates fat storage and production pathways including PPARγ-CD36 and SREBP1C. This discovery fills a significant gap in understanding how liver cells accumulate excessive fat and progress to inflammation and scarring.
What makes this finding particularly promising is the researchers' demonstration of multiple successful therapeutic approaches targeting this pathway. Vaccination, RNA interference, and neutralizing antibodies all prevented and treated MASH in animal models. The variety of potential interventions suggests at least one could translate successfully to human trials.
This represents more than incremental progress—identifying a completely novel pathogenic pathway opens therapeutic avenues that bypass the limitations of current approaches focused on symptoms rather than underlying drivers of disease progression.